Fatty Liver a Major Health Risk: Experts
Nonalcoholic fatty liver disease refers to a range of conditions in which fatty deposits occur in the liver. (Representational Image)Nonalcoholic fatty liver disease refers to a range of conditions in which fatty deposits occur in the liver. (Representational Image) �Hyderabad: Fatty liver disease, once considered a minor issue, has now emerged as a serious public […]
Study: Real-world results of GLP-1 drugs don’t match trials
Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says.
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than three years. Mounjaro and Zepbound include the same compound tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro and Zepbound generated combined sales […]
Reality check: Unpacking the $150B GLP-1 market forecasts
Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric. Last month, Morgan Stanley Research upped its 2035 peak estimate for the obesity drug …
Cleveland Clinic Research Finds Injectable Medications for Obesity Produce Smaller Weight Loss in A Real-World Setting, Compared to Randomized Clinical Trials – Cleveland Clinic Newsroom
Cleveland Clinic Research Finds Injectable Medications for Obesity Produce Smaller Weight Loss in A Real-World Setting, Compared to Randomized Clinical Trials Cleveland Clinic Newsroom Real-World Use of GLP-1s Yields Less Weight Loss Than Clinical Trials AJMC Real-World Results For GLP-1 Drugs Underwhelm, Study Says U.S. News & World Report Weight loss drugs don’t work as well for people […]
Use of GLP-1 RAs is associated with a 2-fold higher risk of Macular Degeneration
Comments
Virta Health Survey Reveals Secret to Lasting Weight Loss After GLP-1s: Users Who Follow a Guided Off-ramp are 8x More Likely to Continue Losing Weight
DENVER–(BUSINESS WIRE)–Virta Health, a leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, today released a report showing that people can maintain weight loss after stopping GLP-1 medication with the right guidance and lifestyle support—challenging the belief that weight regain is inevitable. Critically, the survey found those who tapered off GLP-1s under […]
Real-World Results For GLP-1 Drugs Underwhelm, Study Says
By Dennis Thompson HealthDay ReporterWEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic,…
Why Omada Health is resisting an AI takeover after its IPO
Omada Health’s president Wei-Li Shao and CEO Sean Duffy at the company’s June 6 IPO. Omada Health AI is taking over healthcare, but Omada Health is pushing back. Unlike some of its peers, Omada Health says it won’t let AI take over care delivery. The chronic care startup went public on Friday, marking the second […]
How to keep weight off after obesity drugs
Nature, Published online: 11 June 2025; doi:10.1038/d41586-025-01770-0 Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.